Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Evaluation of hGM-CSF/hTNFα surface-modified prostate cancer therapeutic vaccine in the huPBL-SCID chimeric mouse model

Fig. 1

Therapeutic effects of hGM-CSF or/and hTNFα modified PC-3 cell vaccines on human prostate cancer in the huPBL-SCID mouse model. After inoculation with PC-3 prostate cancer cell vaccine, huPBL-SCID mice were treated i.p. with PC-3 cancer cell vaccines or PBS on days 0, 7, and 14. We collected and weighted the tumors in the mice died at different time points or those still living on day 60 (p < 0.05). There were no data at the time point on day 60 in the PBS control group because all mice died before/on day 56 (a). In addition, we drew a curve of the mean size of cross-sectional area of the tumors in each group along with the time period (b). Meanwhile, we recorded the time of all mice death with the day of injecting PC-3 cancer cells as the starting point and drew survival curves (p < 0.05) (c). The results represented one of three separate experiments

Back to article page